血清CA125对卵巢癌的诊断价值及与临床分期的相关性研究.docVIP

精品论文 参考文献 血清CA125对卵巢癌的诊断价值及与临床分期的相关性研究 王小玉 （安徽省六安市人民医院妇产科 237005） 【摘要】目的 观察CA125、CA19-9、CA72-4在卵巢癌患者中的诊断价值，分析CA125水平与卵巢癌临床分期之间的相关性。方法 采用电发光法检测63例卵巢癌及60例卵巢良性肿瘤患者血清CA125、CA19-9、CA72-4水平。结果 联合检测血清CA125、CA19-9、CA72-4的敏感性及特异性显著高于单项检测（Plt;0.05）；随着临床分期的增加，血清CA125水平逐渐升高。结论 联合检测血清CA125、CA19-9、CA72-4对卵巢癌的诊断和鉴别诊断具有重要价值，值得临床推广应用；CA125对卵巢癌的病情评估具有重要指导作用。 【关键词】卵巢癌 CA125 CA19-9 CA72-4 联合检测 临床分期 【中图分类号】R730.4 【文献标识码】A 【文章编号】2095-1752（2013）21-0120-02 Analysis of the diagnostic value of the serum CA125 in ovarian carcinoma and the relationship between it and clinical stage of ovarian carcinoma. 【Abstract】 Objective To explore the significance of serum CA125, CA19-9 and CA72-4 in diagnosis of ovarian carcinoma; To investigate the relationship between the serum CA125 and the clinical stage of ovarian carcinoma. Methods The serum levels of CA125, CA19-9 and CA72-4 of 63 patients with ovarian carcinoma, 60 patients with benign ovarian tumor were detected by electrochemical method. Results The sensitivity and specificity of CA125, CA19-9 and CA72-4 combined detection was higher than that of single detection(Plt;0.05); With increasing of clinical stages, the level of serum CA125 is increasing gradually. Conclusion The combined detection of serum CA125, CA19-9 and CA72-4 has the important values in diagnosis and differential diagnosis of ovarian tumors, and is worthy of clinical application; The serum CA125 has important guiding role in disease assessment of ovarian cancer. 【Key words】Ovarian cancer CA125 CA19-9 CA72-4 Combined detection Clinical stage 卵巢恶性肿瘤是女性生殖系统常见的恶性肿瘤之一，因其早期症状隐匿，60%-70%患者就诊时多是III-IV期，而晚期病例又疗效不佳[1]。故虽其发病率较宫颈癌和子宫内膜癌低，死亡率却高居女性生殖系统恶性肿瘤之首。可见，早期诊断对卵巢癌的治疗及预后显得尤为重要。 癌抗原125（CA125）是卵巢癌中发现最早的一种肿瘤标记物，尤其作为上皮性卵巢癌的重要肿瘤指标，其在临床上已得到广泛应用，在卵巢恶性肿瘤的诊断、疗效评价及疾病监测等各个方面发挥着重要作用[2、3]。尽管其临床价值已得到充分肯定，但仍有部分早期卵巢癌患者血清中不表达或很少表达CA125[4]，因此，检测其他相关肿瘤标记物，或与CA125联合检测已成为目前研究热点，这也将进一步提高卵巢癌的筛查敏感性和特异性[5、6]。本文